NGS-Based Monitoring and Diagnostic Test is based on the NGS, aiming for the monitoring and diagnostic test. Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionised genomic research. Using NGS an entire human genome can be sequenced within a single day.
Highlights
The global NGS-Based Monitoring and Diagnostic Test market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for NGS-Based Monitoring and Diagnostic Test is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for NGS-Based Monitoring and Diagnostic Test is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for NGS-Based Monitoring and Diagnostic Test in Out-Patient Clinics/General Practitioners is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of NGS-Based Monitoring and Diagnostic Test include Agilent Technologies, Inc., Ancestry LLC, ArcherDX, Inc., Beijing Genomics Institute (BGI), Cancer Genetics, Inc., CENTOGENE AG, F. Hoffmann-La Roche Ltd, GenePath Dx and Illumina, Inc., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for NGS-Based Monitoring and Diagnostic Test, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NGS-Based Monitoring and Diagnostic Test.
The NGS-Based Monitoring and Diagnostic Test market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global NGS-Based Monitoring and Diagnostic Test market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the NGS-Based Monitoring and Diagnostic Test companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Agilent Technologies, Inc.
Ancestry LLC
ArcherDX, Inc.
Beijing Genomics Institute (BGI)
Cancer Genetics, Inc.
CENTOGENE AG
F. Hoffmann-La Roche Ltd
GenePath Dx
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Siemens Healthineers, Inc.
Thermo Fisher Scientific Inc.
HTG Molecular Diagnostics, Inc.
Vela Diagnostics Pte. Ltd.
Segment by Type
Commercial Assays/Tests
Laboratory Developed Tests
Direct to Consumer Test
Pre-Commercial Tests
Segment by Application
Out-Patient Clinics/General Practitioners
Diagnostic Centers
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of NGS-Based Monitoring and Diagnostic Test companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global NGS-Based Monitoring and Diagnostic Test Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Commercial Assays/Tests
1.2.3 Laboratory Developed Tests
1.2.4 Direct to Consumer Test
1.2.5 Pre-Commercial Tests
1.3 Market by Application
1.3.1 Global NGS-Based Monitoring and Diagnostic Test Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Out-Patient Clinics/General Practitioners
1.3.3 Diagnostic Centers
1.3.4 Hospitals
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global NGS-Based Monitoring and Diagnostic Test Market Perspective (2018-2029)
2.2 NGS-Based Monitoring and Diagnostic Test Growth Trends by Region
2.2.1 Global NGS-Based Monitoring and Diagnostic Test Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 NGS-Based Monitoring and Diagnostic Test Historic Market Size by Region (2018-2023)
2.2.3 NGS-Based Monitoring and Diagnostic Test Forecasted Market Size by Region (2024-2029)
2.3 NGS-Based Monitoring and Diagnostic Test Market Dynamics
2.3.1 NGS-Based Monitoring and Diagnostic Test Industry Trends
2.3.2 NGS-Based Monitoring and Diagnostic Test Market Drivers
2.3.3 NGS-Based Monitoring and Diagnostic Test Market Challenges
2.3.4 NGS-Based Monitoring and Diagnostic Test Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top NGS-Based Monitoring and Diagnostic Test Players by Revenue
3.1.1 Global Top NGS-Based Monitoring and Diagnostic Test Players by Revenue (2018-2023)
3.1.2 Global NGS-Based Monitoring and Diagnostic Test Revenue Market Share by Players (2018-2023)
3.2 Global NGS-Based Monitoring and Diagnostic Test Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by NGS-Based Monitoring and Diagnostic Test Revenue
3.4 Global NGS-Based Monitoring and Diagnostic Test Market Concentration Ratio
3.4.1 Global NGS-Based Monitoring and Diagnostic Test Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by NGS-Based Monitoring and Diagnostic Test Revenue in 2022
3.5 NGS-Based Monitoring and Diagnostic Test Key Players Head office and Area Served
3.6 Key Players NGS-Based Monitoring and Diagnostic Test Product Solution and Service
3.7 Date of Enter into NGS-Based Monitoring and Diagnostic Test Market
3.8 Mergers & Acquisitions, Expansion Plans
4 NGS-Based Monitoring and Diagnostic Test Breakdown Data by Type
4.1 Global NGS-Based Monitoring and Diagnostic Test Historic Market Size by Type (2018-2023)
4.2 Global NGS-Based Monitoring and Diagnostic Test Forecasted Market Size by Type (2024-2029)
5 NGS-Based Monitoring and Diagnostic Test Breakdown Data by Application
5.1 Global NGS-Based Monitoring and Diagnostic Test Historic Market Size by Application (2018-2023)
5.2 Global NGS-Based Monitoring and Diagnostic Test Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America NGS-Based Monitoring and Diagnostic Test Market Size (2018-2029)
6.2 North America NGS-Based Monitoring and Diagnostic Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America NGS-Based Monitoring and Diagnostic Test Market Size by Country (2018-2023)
6.4 North America NGS-Based Monitoring and Diagnostic Test Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe NGS-Based Monitoring and Diagnostic Test Market Size (2018-2029)
7.2 Europe NGS-Based Monitoring and Diagnostic Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe NGS-Based Monitoring and Diagnostic Test Market Size by Country (2018-2023)
7.4 Europe NGS-Based Monitoring and Diagnostic Test Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market Size (2018-2029)
8.2 Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market Size by Region (2018-2023)
8.4 Asia-Pacific NGS-Based Monitoring and Diagnostic Test Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America NGS-Based Monitoring and Diagnostic Test Market Size (2018-2029)
9.2 Latin America NGS-Based Monitoring and Diagnostic Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America NGS-Based Monitoring and Diagnostic Test Market Size by Country (2018-2023)
9.4 Latin America NGS-Based Monitoring and Diagnostic Test Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Market Size (2018-2029)
10.2 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Market Size by Country (2018-2023)
10.4 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent Technologies, Inc.
11.1.1 Agilent Technologies, Inc. Company Detail
11.1.2 Agilent Technologies, Inc. Business Overview
11.1.3 Agilent Technologies, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.1.4 Agilent Technologies, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.1.5 Agilent Technologies, Inc. Recent Development
11.2 Ancestry LLC
11.2.1 Ancestry LLC Company Detail
11.2.2 Ancestry LLC Business Overview
11.2.3 Ancestry LLC NGS-Based Monitoring and Diagnostic Test Introduction
11.2.4 Ancestry LLC Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.2.5 Ancestry LLC Recent Development
11.3 ArcherDX, Inc.
11.3.1 ArcherDX, Inc. Company Detail
11.3.2 ArcherDX, Inc. Business Overview
11.3.3 ArcherDX, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.3.4 ArcherDX, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.3.5 ArcherDX, Inc. Recent Development
11.4 Beijing Genomics Institute (BGI)
11.4.1 Beijing Genomics Institute (BGI) Company Detail
11.4.2 Beijing Genomics Institute (BGI) Business Overview
11.4.3 Beijing Genomics Institute (BGI) NGS-Based Monitoring and Diagnostic Test Introduction
11.4.4 Beijing Genomics Institute (BGI) Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.4.5 Beijing Genomics Institute (BGI) Recent Development
11.5 Cancer Genetics, Inc.
11.5.1 Cancer Genetics, Inc. Company Detail
11.5.2 Cancer Genetics, Inc. Business Overview
11.5.3 Cancer Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.5.4 Cancer Genetics, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.5.5 Cancer Genetics, Inc. Recent Development
11.6 CENTOGENE AG
11.6.1 CENTOGENE AG Company Detail
11.6.2 CENTOGENE AG Business Overview
11.6.3 CENTOGENE AG NGS-Based Monitoring and Diagnostic Test Introduction
11.6.4 CENTOGENE AG Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.6.5 CENTOGENE AG Recent Development
11.7 F. Hoffmann-La Roche Ltd
11.7.1 F. Hoffmann-La Roche Ltd Company Detail
11.7.2 F. Hoffmann-La Roche Ltd Business Overview
11.7.3 F. Hoffmann-La Roche Ltd NGS-Based Monitoring and Diagnostic Test Introduction
11.7.4 F. Hoffmann-La Roche Ltd Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.7.5 F. Hoffmann-La Roche Ltd Recent Development
11.8 GenePath Dx
11.8.1 GenePath Dx Company Detail
11.8.2 GenePath Dx Business Overview
11.8.3 GenePath Dx NGS-Based Monitoring and Diagnostic Test Introduction
11.8.4 GenePath Dx Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.8.5 GenePath Dx Recent Development
11.9 Illumina, Inc.
11.9.1 Illumina, Inc. Company Detail
11.9.2 Illumina, Inc. Business Overview
11.9.3 Illumina, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.9.4 Illumina, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.9.5 Illumina, Inc. Recent Development
11.10 Laboratory Corporation of America Holdings
11.10.1 Laboratory Corporation of America Holdings Company Detail
11.10.2 Laboratory Corporation of America Holdings Business Overview
11.10.3 Laboratory Corporation of America Holdings NGS-Based Monitoring and Diagnostic Test Introduction
11.10.4 Laboratory Corporation of America Holdings Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.10.5 Laboratory Corporation of America Holdings Recent Development
11.11 Myriad Genetics, Inc.
11.11.1 Myriad Genetics, Inc. Company Detail
11.11.2 Myriad Genetics, Inc. Business Overview
11.11.3 Myriad Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.11.4 Myriad Genetics, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.11.5 Myriad Genetics, Inc. Recent Development
11.12 QIAGEN N.V.
11.12.1 QIAGEN N.V. Company Detail
11.12.2 QIAGEN N.V. Business Overview
11.12.3 QIAGEN N.V. NGS-Based Monitoring and Diagnostic Test Introduction
11.12.4 QIAGEN N.V. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.12.5 QIAGEN N.V. Recent Development
11.13 Quest Diagnostics Incorporated
11.13.1 Quest Diagnostics Incorporated Company Detail
11.13.2 Quest Diagnostics Incorporated Business Overview
11.13.3 Quest Diagnostics Incorporated NGS-Based Monitoring and Diagnostic Test Introduction
11.13.4 Quest Diagnostics Incorporated Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.13.5 Quest Diagnostics Incorporated Recent Development
11.14 Siemens Healthineers, Inc.
11.14.1 Siemens Healthineers, Inc. Company Detail
11.14.2 Siemens Healthineers, Inc. Business Overview
11.14.3 Siemens Healthineers, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.14.4 Siemens Healthineers, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.14.5 Siemens Healthineers, Inc. Recent Development
11.15 Thermo Fisher Scientific Inc.
11.15.1 Thermo Fisher Scientific Inc. Company Detail
11.15.2 Thermo Fisher Scientific Inc. Business Overview
11.15.3 Thermo Fisher Scientific Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.15.4 Thermo Fisher Scientific Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.15.5 Thermo Fisher Scientific Inc. Recent Development
11.16 HTG Molecular Diagnostics, Inc.
11.16.1 HTG Molecular Diagnostics, Inc. Company Detail
11.16.2 HTG Molecular Diagnostics, Inc. Business Overview
11.16.3 HTG Molecular Diagnostics, Inc. NGS-Based Monitoring and Diagnostic Test Introduction
11.16.4 HTG Molecular Diagnostics, Inc. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.16.5 HTG Molecular Diagnostics, Inc. Recent Development
11.17 Vela Diagnostics Pte. Ltd.
11.17.1 Vela Diagnostics Pte. Ltd. Company Detail
11.17.2 Vela Diagnostics Pte. Ltd. Business Overview
11.17.3 Vela Diagnostics Pte. Ltd. NGS-Based Monitoring and Diagnostic Test Introduction
11.17.4 Vela Diagnostics Pte. Ltd. Revenue in NGS-Based Monitoring and Diagnostic Test Business (2018-2023)
11.17.5 Vela Diagnostics Pte. Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Agilent Technologies, Inc.
Ancestry LLC
ArcherDX, Inc.
Beijing Genomics Institute (BGI)
Cancer Genetics, Inc.
CENTOGENE AG
F. Hoffmann-La Roche Ltd
GenePath Dx
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Siemens Healthineers, Inc.
Thermo Fisher Scientific Inc.
HTG Molecular Diagnostics, Inc.
Vela Diagnostics Pte. Ltd.
听
听
*If Applicable.
